Dose selection for the investigational anticancer agent alisertib (MLN8237): Pharmacokinetics, pharmacodynamics, and exposure-safety relationships

Investigational Aurora A kinase inhibitor alisertib (MLN8237) as an enteric-coated tablet formulation in non-hematologic malignancies: Phase 1 dose-escalation study

(2014) Gerald Falchook et al.   INVESTIGATIONAL NEW DRUGS

Fixed-dose capecitabine is feasible: results from a pharmacokinetic and pharmacogenetic study in metastatic breast cancer

(2013) Michelle A. Rudek et al.   BREAST CANCER RESEARCH AND TREATMENT

Preclinical pharmacokinetic/pharmacodynamic/efficacy relationships for alisertib, an investigational small-molecule inhibitor of Aurora A kinase

(2013) Santhosh Palani et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Phase I Study of Pazopanib in Patients with Advanced Solid Tumors and Hepatic Dysfunction: A National Cancer Institute Organ Dysfunction Working Group Study

(2013) S. I. Shibata et al.   CLINICAL CANCER RESEARCH

Phase I study of MLN8237—investigational Aurora A kinase inhibitor—in relapsed/refractory multiple myeloma, Non-Hodgkin lymphoma and chronic lymphocytic leukemia

(2013) Kevin R. Kelly et al.   INVESTIGATIONAL NEW DRUGS

Identification of an Aurora Kinase Inhibitor Specific for the Aurora B Isoform

(2012) H. Xie et al.   CANCER RESEARCH

Pharmacokinetics and Safety of Bortezomib in Patients with Advanced Malignancies and Varying Degrees of Liver Dysfunction: Phase I NCI Organ Dysfunction Working Group Study NCI-6432

(2012) P. M. LoRusso et al.   CLINICAL CANCER RESEARCH

Phase I Pharmacokinetic/Pharmacodynamic Study of MLN8237, an Investigational, Oral, Selective Aurora A Kinase Inhibitor, in Patients with Advanced Solid Tumors

(2012) A. Cervantes et al.   CLINICAL CANCER RESEARCH

Phase I Study of Aurora A Kinase Inhibitor MLN8237 in Advanced Solid Tumors: Safety, Pharmacokinetics, Pharmacodynamics, and Bioavailability of Two Oral Formulations

(2012) E. C. Dees et al.   CLINICAL CANCER RESEARCH

Phase II study of MLN8237 (alisertib), an investigational Aurora A kinase inhibitor, in patients with platinum-resistant or -refractory epithelial ovarian, fallopian tube, or primary peritoneal carcinoma

(2012) Ursula A. Matulonis et al.   GYNECOLOGIC ONCOLOGY

Inhibiting Aurora Kinases Reduces Tumor Growth and Suppresses Tumor Recurrence after Chemotherapy in Patient-Derived Triple-Negative Breast Cancer Xenografts

(2012) A. Romanelli et al.   MOLECULAR CANCER THERAPEUTICS

Efficacy and pharmacokinetic/pharmacodynamic evaluation of the Aurora kinase A inhibitor MLN8237 against preclinical models of pediatric cancer

(2011) Hernan Carol et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Characterization of Alisertib (MLN8237), an Investigational Small-Molecule Inhibitor of Aurora A Kinase Using Novel In Vivo Pharmacodynamic Assays

(2011) M. G. Manfredi et al.   CLINICAL CANCER RESEARCH

Population Differences in Major Functional Polymorphisms of Pharmacokinetics/pharmacodynamics-related Genes in Eastern Asians and Europeans: Implications in the Clinical Trials for Novel Drug Development

(2011) Kouichi Kurose et al.   Drug Metabolism and Pharmacokinetics

Functional Significance of Aurora Kinase A Regulatory Interactions with p53–ERα Complex in Human Breast Cancer Cells

(2011) Hiroshi Katayama et al.   Hormones & Cancer

A novel Aurora-A kinase inhibitor MLN8237 induces cytotoxicity and cell-cycle arrest in multiple myeloma

(2010) G. Gorgun et al.   BLOOD

Phase I Assessment of New Mechanism-Based Pharmacodynamic Biomarkers for MLN8054, a Small-Molecule Inhibitor of Aurora A Kinase

(2010) A. Chakravarty et al.   CANCER RESEARCH

MLN8054, an Inhibitor of Aurora A Kinase, Induces Senescence in Human Tumor Cells Both In vitro and In vivo

(2010) J. J. Huck et al.   MOLECULAR CANCER RESEARCH

Aurora kinase A is a target of Wnt/ -catenin involved in multiple myeloma disease progression

(2009) J. Dutta-Simmons et al.   BLOOD

Comprehensive Pharmacogenetic Analysis of Irinotecan Neutropenia and Pharmacokinetics

(2009) Federico Innocenti et al.   JOURNAL OF CLINICAL ONCOLOGY

Quantitation of Aurora Kinase A Gene Copy Number in Urine Sediments and Bladder Cancer Detection

(2008) Hong-Seok Park et al.   JNCI-Journal of the National Cancer Institute

Aurora A kinase RNAi and small molecule inhibition of Aurora kinases with VE-465 induce apoptotic death in multiple myeloma cells

(2008) Robert Evans et al.   LEUKEMIA & LYMPHOMA